NASDAQ:XERSXeris Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Xeris Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.14 -0.21 (-3.93 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$4.90Now: $5.14▼$5.2850-Day Range$1.65MA: $3.01▼$5.8052-Week Range$1.42Now: $5.14▼$12.94Volume414,496 shsAverage Volume852,798 shsMarket Capitalization$193.21 millionP/E RatioN/ADividend YieldN/ABeta1.66 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that is in Phase II clinical trials for the treatment of congenital hyperinsulinism, post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, and hypoglycemia-associated autonomic failure, as well as for treating hypoglycemia associated with intermittent and chronic conditions, and bi-hormonal artificial pancreas closed-loop systems. In addition, it develops continuous subcutaneous glucagon infusion system of ready-to-use glucagon; ready-to-use diazepam formulation, which is in Phase I clinical trial for the treatment of acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is in pre-clinical stage for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingXeris Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.67, Xeris Pharmaceuticals has a potential upside of 185.3% from its current price of $5.14.Amount of Analyst CoverageXeris Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesXeris Pharmaceuticals has received 101 “outperform” votes. (Add your “outperform” vote.)Underperform VotesXeris Pharmaceuticals has received 106 “underperform” votes. (Add your “underperform” vote.)Community SentimentXeris Pharmaceuticals has received 51.21% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Xeris Pharmaceuticals and other stocks. Vote “Outperform” if you believe XERS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe XERS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldXeris Pharmaceuticals does not currently pay a dividend.Dividend GrowthXeris Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xeris Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $194,920.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.43% of the stock of Xeris Pharmaceuticals is held by insiders.Percentage Held by Institutions62.48% of the stock of Xeris Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Xeris Pharmaceuticals are expected to grow in the coming year, from ($3.06) to ($1.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xeris Pharmaceuticals is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xeris Pharmaceuticals is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXeris Pharmaceuticals has a P/B Ratio of 7.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.11 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XERS Previous Symbol CUSIPN/A CIKN/A Webwww.xerispharma.com Phone844-445-5704Debt Debt-to-Equity Ratio2.16 Current Ratio4.82 Quick Ratio4.72Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.72 million Price / Sales71.03 Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book7.14Profitability EPS (Most Recent Fiscal Year)($4.81) Net Income$-125,580,000.00 Net Margins-3,100.00% Return on Equity-323.82% Return on Assets-106.26%Miscellaneous Employees90 Outstanding Shares37,590,000Market Cap$193.21 million Next Earnings Date8/4/2020 (Estimated) OptionableNot Optionable NASDAQ:XERS Rates by TradingView Receive XERS News and Ratings via Email Sign-up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter. Xeris Pharmaceuticals (NASDAQ:XERS) Frequently Asked Questions How has Xeris Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Xeris Pharmaceuticals' stock was trading at $2.22 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, XERS stock has increased by 131.5% and is now trading at $5.14. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Xeris Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xeris Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Xeris Pharmaceuticals. When is Xeris Pharmaceuticals' next earnings date? Xeris Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Xeris Pharmaceuticals. How were Xeris Pharmaceuticals' earnings last quarter? Xeris Pharmaceuticals Inc (NASDAQ:XERS) issued its earnings results on Thursday, May, 7th. The company reported ($0.89) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.92) by $0.03. The business earned $1.68 million during the quarter, compared to analysts' expectations of $1.82 million. Xeris Pharmaceuticals had a negative net margin of 3,100.00% and a negative return on equity of 323.82%. View Xeris Pharmaceuticals' earnings history. What price target have analysts set for XERS? 3 brokerages have issued 1-year target prices for Xeris Pharmaceuticals' stock. Their forecasts range from $12.00 to $18.00. On average, they expect Xeris Pharmaceuticals' share price to reach $14.67 in the next twelve months. This suggests a possible upside of 185.3% from the stock's current price. View analysts' price targets for Xeris Pharmaceuticals. What are Wall Street analysts saying about Xeris Pharmaceuticals stock? Here are some recent quotes from research analysts about Xeris Pharmaceuticals stock: 1. According to Zacks Investment Research, "Xeris Pharmaceuticals, Inc. produces peptides, proteins, antibodies, molecules, auto-injectors, multi-dose pens and infusion pumps to treat endocrine and metabolic diseases. The company's proprietary formulation technologies consist of XeriSol (TM) and XeriJect(TM). Xeris Pharmaceuticals, Inc. is based in Chicago, United States. " (5/16/2020) 2. Mizuho analysts commented, "We applied a weighted average valuation methodology (DCF+EV/Sales) to derive our $27 PT. Our assumptions include: Launch of the glucagon rescue pen in the U.S. market in 4Q19, with unadjusted peak-sales of $454 mil in 2028 (current PoS: 90%)." (9/10/2019) Has Xeris Pharmaceuticals been receiving favorable news coverage? Headlines about XERS stock have been trending extremely negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Xeris Pharmaceuticals earned a news impact score of -4.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutXeris Pharmaceuticals. Who are some of Xeris Pharmaceuticals' key competitors? Some companies that are related to Xeris Pharmaceuticals include Collegium Pharmaceutical (COLL), Cara Therapeutics (CARA), Akero Therapeutics (AKRO), Kadmon (KDMN), Molecular Templates (MTEM), Eagle Pharmaceuticals (EGRX), Retrophin (RTRX), Kala Pharmaceuticals (KALA), Ardelyx (ARDX), Provention Bio (PRVB), Homology Medicines (FIXX), G1 Therapeutics (GTHX), Vanda Pharmaceuticals (VNDA), Assembly Biosciences (ASMB) and Morphic (MORF). View all competitors. What other stocks do shareholders of Xeris Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Pharmaceuticals investors own include Pfizer (PFE), Gilead Sciences (GILD), Myovant Sciences (MYOV), NVIDIA (NVDA), Opko Health (OPK), AbbVie (ABBV), Sorrento Therapeutics (SRNE), Applied Genetic Technologies (AGTC), Advanced Micro Devices (AMD) and Dynavax Technologies (DVAX). Who are Xeris Pharmaceuticals' key executives? Xeris Pharmaceuticals' management team includes the following people: Mr. Paul R. Edick, Pres, CEO & Chairman (Age 63)Mr. Barry M. Deutsch, Chief Financial Officer (Age 54)Mr. John P. Shannon, Exec. VP & COO (Age 57)Dr. Steven J. Prestrelski, Co-Founder & Chief Scientific Officer (Age 55)Ms. Allison Wey, Sr. VP of Investor Relations & Corp. Communications When did Xeris Pharmaceuticals IPO? (XERS) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager. What is Xeris Pharmaceuticals' stock symbol? Xeris Pharmaceuticals trades on the NASDAQ under the ticker symbol "XERS." Who are Xeris Pharmaceuticals' major shareholders? Xeris Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Redmile Group LLC (7.87%), ArrowMark Colorado Holdings LLC (6.23%), BlackRock Inc. (6.22%), State Street Corp (1.44%), Alpine Global Management LLC (1.35%) and Geode Capital Management LLC (1.30%). Company insiders that own Xeris Pharmaceuticals stock include Beth Hecht, James E Flynn, John Patrick Shannon Jr, Palmetto Partners, Ltd, Paul R Edick, Redmile Group, Llc and Steven Prestrelski. View institutional ownership trends for Xeris Pharmaceuticals. Which major investors are selling Xeris Pharmaceuticals stock? XERS stock was sold by a variety of institutional investors in the last quarter, including Blackstone Group Inc, Wells Fargo & Company MN, Redmile Group LLC, Parametric Portfolio Associates LLC, and UBS Group AG. View insider buying and selling activity for Xeris Pharmaceuticals. Which major investors are buying Xeris Pharmaceuticals stock? XERS stock was bought by a variety of institutional investors in the last quarter, including Alpine Global Management LLC, ArrowMark Colorado Holdings LLC, Two Sigma Investments LP, BlackRock Inc., Geode Capital Management LLC, Nuveen Asset Management LLC, Searle & CO., and IHT Wealth Management LLC. Company insiders that have bought Xeris Pharmaceuticals stock in the last two years include Beth Hecht, James E Flynn, John Patrick Shannon Jr, Palmetto Partners, Ltd, Paul R Edick, and Redmile Group, Llc. View insider buying and selling activity for Xeris Pharmaceuticals. How do I buy shares of Xeris Pharmaceuticals? Shares of XERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Xeris Pharmaceuticals' stock price today? One share of XERS stock can currently be purchased for approximately $5.14. How big of a company is Xeris Pharmaceuticals? Xeris Pharmaceuticals has a market capitalization of $193.21 million and generates $2.72 million in revenue each year. The company earns $-125,580,000.00 in net income (profit) each year or ($4.81) on an earnings per share basis. Xeris Pharmaceuticals employs 90 workers across the globe. What is Xeris Pharmaceuticals' official website? The official website for Xeris Pharmaceuticals is www.xerispharma.com. How can I contact Xeris Pharmaceuticals? Xeris Pharmaceuticals' mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The company can be reached via phone at 844-445-5704 or via email at [email protected] This page was last updated on 5/31/2020 by MarketBeat.com Staff
